Long term oncological outcome of thymoma and thymic carcinoma – an analysis of 235 cases from a single institution

Autor: Han Shui Hsu, Hua Lin Kao, Yih Gang Goan, Teh Ying Chou, Yen Chiang Tseng, Wen Hu Hsu, Yen Han Tseng, Chih-Cheng Hsieh
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Clinical Oncology
medicine.medical_specialty
Thymoma
Histology
medicine.medical_treatment
Immunology
Cancer Treatment
lcsh:Medicine
Surgical and Invasive Medical Procedures
030204 cardiovascular system & hematology
Carcinomas
Lung and Intrathoracic Tumors
Autoimmune Diseases
03 medical and health sciences
0302 clinical medicine
Thymic Tumors
Myasthenia Gravis
Adjuvant therapy
Medicine and Health Sciences
Medicine
Stage (cooking)
lcsh:Science
Survival rate
Thymic carcinoma
Univariate analysis
Multidisciplinary
Surgical Resection
business.industry
lcsh:R
Cancers and Neoplasms
Biology and Life Sciences
medicine.disease
Tumor Resection
Surgery
Thymectomy
Surgical Oncology
Oncology
Median sternotomy
030220 oncology & carcinogenesis
lcsh:Q
Clinical Immunology
Clinical Medicine
Anatomy
business
Research Article
Zdroj: PLoS ONE
PLoS ONE, Vol 12, Iss 6, p e0179527 (2017)
ISSN: 1932-6203
Popis: Background and objectives Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence. Methods A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS). Results The median duration of follow-up was 105 months (12–198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7%). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5%), 8/106(7.5%), 1/32(3.1%), 6/20(30.0%), 8/10(80.0%), 1/1(100.0%), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4%. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status. Conclusions Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.
Databáze: OpenAIRE
Externí odkaz: